remibrutinib vs Tolebrutinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: Bruton's tyrosine kinase (BTK) · full Multiple Sclerosis pipeline

remibrutinib

Marketed by Novartis

Phase 3 in Multiple Sclerosissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2029 · NCT06846281 (registry estimate)

No aligned efficacy figure on record for this race.

Tolebrutinib

Marketed by Sanofi

Phase 3 in Multiple Sclerosissmall molecule
Reliable signal

NCT04411641 · Phase 3 · completed

The trial randomized 1,131 participants in a 2:1 ratio to double-blind tolebrutinib or matching placebo, with participants, investigators, and outcome assessors masked. Its primary clinical endpoint—6-month confirmed disability progression measured by EDSS—was statistically met, with a hazard ratio of 0.693 (95% CI 0.546–0.880; p=0.0026).

Next expected readout: April 2029 · NCT06372145 (registry estimate)

Reported efficacy

Time to Onset of 6-Month Confirmed Disability Progression (CDP) as Assessed by Expanded Disability Status Scale (EDSS) (Baseline (Day 1) up to approximately 47 months): HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results). (met)

Result source: NCT04411641

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointremibrutinibTolebrutinib
Annualised relapse rate—Trial running · NCT072255040.1 vs 0.1vs Teriflunomide60 mg · wk 208 · n 486NCT04410978
1 other result
  • 0.1 vs 0.1 60 mg · wk 208 · n 447 · Phase 3 · primary NCT04410991
Free of 3-month confirmed disability progression (%)—Trial running · NCT07225504—Not posted · NCT04458051
New or enlarging T2 lesions—Trial running · NCT072255040.2 vs 2.1−1.9 vs placebo60 mg · n 31NCT03889639
3 other results
  • 1.3 vs 2.1 30 mg · n 33 · Phase 2 · secondary NCT03889639
  • 1.3 vs 2.1 15 mg · n 31 · Phase 2 · secondary NCT03889639
  • 1.9 vs 2.1 5 mg · n 31 · Phase 2 · secondary NCT03889639

Annualised relapse rate

remibrutinib
—Trial running · NCT07225504
Tolebrutinib
0.1 vs 0.1vs Teriflunomide60 mg · wk 208 · n 486NCT04410978
1 other result
  • 0.1 vs 0.1 60 mg · wk 208 · n 447 · Phase 3 · primary NCT04410991

Free of 3-month confirmed disability progression (%)

remibrutinib
—Trial running · NCT07225504
Tolebrutinib
—Not posted · NCT04458051

New or enlarging T2 lesions

remibrutinib
—Trial running · NCT07225504
Tolebrutinib
0.2 vs 2.1−1.9 vs placebo60 mg · n 31NCT03889639
3 other results
  • 1.3 vs 2.1 30 mg · n 33 · Phase 2 · secondary NCT03889639
  • 1.3 vs 2.1 15 mg · n 31 · Phase 2 · secondary NCT03889639
  • 1.9 vs 2.1 5 mg · n 31 · Phase 2 · secondary NCT03889639
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

remibrutinib: no structured comparison results are available for Multiple Sclerosis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. remibrutinib: 0 of 4 rows · Tolebrutinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTolebrutinib
Dropout rate
42.4%60 mga
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 14 more results
15.8%60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
14.1%60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0%60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—15/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—30/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—5/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—60/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
3.2%5 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—60 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—30 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—15 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—5 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.8%60 mga
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 14 more results
—60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
—60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
—60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—15/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—30/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—5/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—60/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—30 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—15 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—5 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
—60 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—30 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—15 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
—5 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
Serious AEs
15%60 mga
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 14 more results
8.6%60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
11%60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
6.5%60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
9.7%15/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
9.4%30/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
16.7%5/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
9.7%60/60 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
3.1%30 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
6.5%15 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT03996291 · Phase 2 · registry result, not featured evidence
3.1%60 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT03889639 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
60 mga
covid-19 24.6% (placebo 22.7%)
urinary tract infection 10.9% (placebo 13.1%)
fall 9.3% (placebo 10.7%)
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 14 more results
60 mg
covid-19 24.1%
nasopharyngitis 12.1%
headache 11.5%
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
60 mg
covid-19 23.7%
headache 13.6%
nasopharyngitis 13.4%
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
60 mg
viral upper respiratory tract infection 16.1%
headache 9.7%
back pain 6.5%
NCT03996291 · Phase 2 · registry result, not featured evidence
15/60 mg
covid-19 32.3%
nasopharyngitis 19.4%
back pain 16.1%
NCT03996291 · Phase 2 · registry result, not featured evidence
30/60 mg
covid-19 21.9%
urinary tract infection 15.6%
hypertension 12.5%
NCT03996291 · Phase 2 · registry result, not featured evidence
5/60 mg
covid-19 33.3%
back pain 20%
nasopharyngitis 16.7%
NCT03996291 · Phase 2 · registry result, not featured evidence
60/60 mg
covid-19 45.2%
nasopharyngitis 19.4%
arthralgia 16.1%
NCT03996291 · Phase 2 · registry result, not featured evidence
30 mg
headache 12.5%
nasopharyngitis 9.4%
pyrexia 6.3%
NCT03996291 · Phase 2 · registry result, not featured evidence
15 mg
tension headache 6.5%
upper respiratory tract infection 6.5%
fall 3.2%
NCT03996291 · Phase 2 · registry result, not featured evidence
5 mg
headache 9.7%
dry skin 6.5%
pyrexia 6.5%
NCT03996291 · Phase 2 · registry result, not featured evidence
60 mg
headache 12.5% (placebo 3.1%)
accidental overdose 9.4% (placebo 0%)
nasopharyngitis 9.4% (placebo 1.6%)
NCT03889639 · Phase 2 · registry result, not featured evidence
30 mg
back pain 6.1% (placebo 0%)
acne 3% (placebo 0%)
alanine aminotransferase increased 3% (placebo 0%)
NCT03889639 · Phase 2 · registry result, not featured evidence
15 mg
headache 9.4% (placebo 3.1%)
rhinitis 6.3% (placebo 0%)
upper respiratory tract infection 6.3% (placebo 0%)
NCT03889639 · Phase 2 · registry result, not featured evidence
5 mg
oedema peripheral 6.1% (placebo 3.1%)
upper respiratory tract infection 6.1% (placebo 0%)
alanine aminotransferase increased 3% (placebo 0%)
NCT03889639 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 12 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Tolebrutinib

Time to CDP 6mo 12.04 vs 11.97 placebo months60 mg
time to event · months
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
Time to 3m Confirmed Disability Worsening 12.04 vs 11.96 placebo months60 mg
time to event · months
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 2 more results
14.93 vs 17.96 Teriflunomide months60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
12.11 vs 12.11 Teriflunomide months60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Time to HPT 20% Increase 12.21 vs 12.39 placebo months60 mg
time to event · months
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
Time to T25-FW 20% Increase 9.54 vs 9.25 placebo months60 mg
time to event · months
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
Time to 6m Confirmed Disability Improvement 11.89 vs 12.04 placebo months60 mg
time to event · months
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 2 more results
11.82 vs 12.04 Teriflunomide months60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
9.04 vs 12.05 Teriflunomide months60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Brain Volume -0.694% (n=451) vs -0.776% (n=223) placebo @ 204wk60 mg
percent change · % of baseline
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 1 more result
-0.688% (n=351) vs -0.884% (n=346) Teriflunomide @ 208wk60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
SDMT 0.136 vs 0.171 placebo score @ 204wk60 mg
absolute change · score
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 2 more results
0.364 vs 0.329 Teriflunomide score @ 208wk60 mg
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
0.374 vs 0.428 Teriflunomide score @ 208wk60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
CVLT-II 14.169 vs 13.448 placebo score @ 204wk60 mg
absolute change · score
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
MSQoL-54 -3.455 vs -3.979 placebo score @ 204wk60 mg
absolute change · score
Physical health composite score
NCT04411641 · Phase 3 · monotherapy · Multiple Sclerosis, Secondary Progressive Multiple Sclerosis · phase 3
show 1 more result
-0.46 vs -2.468 Teriflunomide score @ 208wk60 mg
Physical health composite score
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
Annualized Relapse 0.13 vs 0.122 Teriflunomide per year @ 208wk60 mg
event rate · per year
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
show 1 more result
0.108 vs 0.109 Teriflunomide per year @ 208wk60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Time to 6m Confirmed Disability Worsening 15.38 vs 17.97 Teriflunomide months60 mg
time to event · months
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
show 1 more result
15.12 vs 12.14 Teriflunomide months60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
CVLT-II 17.7 vs 15.827 Teriflunomide T-score @ 208wk60 mg
absolute change · T-score
NCT04410978 · Phase 3 · Multiple Sclerosis · phase 3
show 1 more result
15.819 vs 16.431 Teriflunomide T-score @ 208wk60 mg
NCT04410991 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: remibrutinib's landscape · Tolebrutinib's landscape